Bionime Corporation (4737.TW)
TWD 66.0
(-0.9%)
TWD 66.0
(-0.9%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.69 Billion TWD | 13.87% |
| 2022 | 1.49 Billion TWD | 28.85% |
| 2021 | 1.15 Billion TWD | -1.34% |
| 2020 | 1.17 Billion TWD | 20.11% |
| 2019 | 976.31 Million TWD | -12.4% |
| 2018 | 1.11 Billion TWD | 51.1% |
| 2017 | 737.57 Million TWD | -7.19% |
| 2016 | 794.71 Million TWD | -40.25% |
| 2015 | 1.33 Billion TWD | -22.21% |
| 2014 | 1.71 Billion TWD | -20.24% |
| 2013 | 2.14 Billion TWD | 11.46% |
| 2012 | 1.92 Billion TWD | 74.86% |
| 2011 | 1.1 Billion TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.37 Billion TWD | -10.31% |
| 2024 Q1 | 1.53 Billion TWD | -9.05% |
| 2023 Q3 | 1.76 Billion TWD | 27.79% |
| 2023 FY | 1.69 Billion TWD | 13.87% |
| 2023 Q1 | 1.39 Billion TWD | -6.54% |
| 2023 Q2 | 1.37 Billion TWD | -0.96% |
| 2023 Q4 | 1.69 Billion TWD | -3.73% |
| 2022 Q3 | 1.18 Billion TWD | -1.22% |
| 2022 FY | 1.49 Billion TWD | 28.85% |
| 2022 Q4 | 1.49 Billion TWD | 25.34% |
| 2022 Q2 | 1.2 Billion TWD | 13.98% |
| 2022 Q1 | 1.05 Billion TWD | -8.69% |
| 2021 Q1 | 1.08 Billion TWD | -7.06% |
| 2021 FY | 1.15 Billion TWD | -1.34% |
| 2021 Q3 | 1.25 Billion TWD | 0.39% |
| 2021 Q4 | 1.15 Billion TWD | -8.03% |
| 2021 Q2 | 1.25 Billion TWD | 14.98% |
| 2020 Q1 | 931.39 Million TWD | -4.6% |
| 2020 Q4 | 1.17 Billion TWD | -6.6% |
| 2020 FY | 1.17 Billion TWD | 20.11% |
| 2020 Q2 | 1.02 Billion TWD | 10.58% |
| 2020 Q3 | 1.25 Billion TWD | 21.89% |
| 2019 Q2 | 1.01 Billion TWD | -4.72% |
| 2019 Q4 | 976.31 Million TWD | -4.69% |
| 2019 FY | 976.31 Million TWD | -12.4% |
| 2019 Q1 | 1.06 Billion TWD | -4.27% |
| 2019 Q3 | 1.02 Billion TWD | 0.76% |
| 2018 Q4 | 1.11 Billion TWD | 23.25% |
| 2018 FY | 1.11 Billion TWD | 51.1% |
| 2018 Q3 | 904.26 Million TWD | 28.01% |
| 2018 Q2 | 706.41 Million TWD | -1.45% |
| 2018 Q1 | 716.79 Million TWD | -2.82% |
| 2017 Q3 | 747.96 Million TWD | -2.04% |
| 2017 Q2 | 763.54 Million TWD | -2.0% |
| 2017 Q1 | 779.13 Million TWD | -1.96% |
| 2017 FY | 737.57 Million TWD | -7.19% |
| 2017 Q4 | 737.57 Million TWD | -1.39% |
| 2016 Q3 | 810.29 Million TWD | -7.17% |
| 2016 Q4 | 794.71 Million TWD | -1.92% |
| 2016 FY | 794.71 Million TWD | -40.25% |
| 2016 Q1 | 889.38 Million TWD | -33.14% |
| 2016 Q2 | 872.91 Million TWD | -1.85% |
| 2015 Q1 | 1.71 Billion TWD | 0.0% |
| 2015 Q2 | 1.61 Billion TWD | -5.56% |
| 2015 Q3 | 1.68 Billion TWD | 4.31% |
| 2015 FY | 1.33 Billion TWD | -22.21% |
| 2015 Q4 | 1.33 Billion TWD | -21.04% |
| 2014 Q3 | 1.8 Billion TWD | -5.0% |
| 2014 Q1 | 1.9 Billion TWD | -11.38% |
| 2014 FY | 1.71 Billion TWD | -20.24% |
| 2014 Q4 | 1.71 Billion TWD | -5.26% |
| 2014 Q2 | 1.9 Billion TWD | 0.0% |
| 2013 FY | 2.14 Billion TWD | 11.46% |
| 2013 Q3 | 1.34 Billion TWD | 0.03% |
| 2013 Q4 | 2.14 Billion TWD | 59.58% |
| 2013 Q1 | 1.1 Billion TWD | -42.81% |
| 2013 Q2 | 1.34 Billion TWD | 22.1% |
| 2012 Q1 | 1.91 Billion TWD | 74.02% |
| 2012 FY | 1.92 Billion TWD | 74.86% |
| 2012 Q4 | 1.92 Billion TWD | 0.15% |
| 2012 Q3 | 1.92 Billion TWD | 0.15% |
| 2012 Q2 | 1.91 Billion TWD | 0.19% |
| 2011 Q1 | - TWD | 0.0% |
| 2011 Q4 | 1.1 Billion TWD | 0.0% |
| 2011 FY | 1.1 Billion TWD | 0.0% |
| 2011 Q3 | 1.1 Billion TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 12.56 Million TWD | -13406.366% |
| Maxigen Biotech Inc. | - TWD | -Infinity% |
| SciVision Biotech Inc. | 346.69 Million TWD | -389.576% |
| Pegavision Corporation | 365.09 Million TWD | -364.909% |
| Visco Vision Inc. | 848.86 Million TWD | -99.954% |